A Phase 3 interventional study of Baxdrostat and Placebo in Uncontrolled Hypertension and Resistant Hypertension, sponsored by AstraZeneca. Completed at 263 sites in 29 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.
Among the 18 studies testing baxdrostat in Hypertension, this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 11th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
By country, each count listing its studies:
baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 796 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 197 across the 18 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 2 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
71 studies in Hypertension by AstraZeneca: 4 open now, 6 under way, 3 of them phase 3. Of 65 finished, 15 (23%) have results posted.
Among the 71 studies in Hypertension by AstraZeneca, this one is the 8th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2023, is one of 18 in phase 3, and was the 62nd registered.
AstraZeneca’s Hypertension studies by the year they started, since 1998.
1 of the studies testing baxdrostat in Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing baxdrostat in Hypertension, from their registry updates:
Among AstraZeneca’s 71 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Fulfil at least 1 of the following 2 criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 mg baxdrostat administered orally, once daily (QD).
Drug: Baxdrostat
1 mg baxdrostat administered orally, once daily (QD).
Drug: Baxdrostat
Placebo administered orally, once daily (QD).
Drug: Placebo
Baxdrostat tablet administered orally, once daily (QD). Unit dose strengths: * 1 mg per tablet for 1 mg baxdrostat Arm; * 2 mg per tablet for 2 mg baxdrostat Arm.
Also known as: CIN-107
Placebo tablet matching baxdrostat, administered orally, once daily (QD).
Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat
To assess the effect of 2 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
Change From Baseline in Seated Systolic Blood Pressure for 1 mg Baxdrostat
To assess the effect of 1 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
Change From Randomised Withdrawal Baseline (Week 24) in Seated Systolic Blood Pressure (SBP) for 2 mg Baxdrostat
To assess the effect of 2 mg baxdrostat vs placebo on seated systolic blood pressure (SBP) at 8 weeks after randomised withdrawal (RWD). All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 32
Change From Baseline in Seated SBP for 2 mg Baxdrostat in the Resistant Hypertension Subpopulation
To assess the effect of 2 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 2 mg Baxdrostat
To assess the effect of 2 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
Number of Participants Who Achieved Seated SBP < 130 mmHg for 2 mg Baxdrostat
To assess the effect of 2 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
Change From Baseline in Seated SBP for 1 mg Baxdrostat in the Resistant Hypertension Subpopulation
To assess the effect of 1 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 1 mg Baxdrostat
To assess the effect of 1 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
Number of Participants Who Achieved Seated SBP < 130 mmHg for 1 mg Baxdrostat
To assess the effect of 1 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.
Time frame: At Week 12
The study was done from 22 November 2023 to 05 November 2025. Participants were screened and randomised from 269 study sites across 29 countries. A total of 794 participants were randomised and treated in the study.
| Milestone | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Open-Label Period Weeks 13-24 Baxdrostat 2mg | Open-Label Period Weeks 13-52 Standard of Care | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo | Open-Label Period Weeks 33-52 Baxdrostat 2mg |
|---|---|---|---|---|---|---|---|---|
| Started | 264 | 266 | 264 | 0 | 0 | 0 | 0 | 0 |
| Completed | 245 | 237 | 246 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 19 | 29 | 18 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Open-Label Period Weeks 13-24 Baxdrostat 2mg | Open-Label Period Weeks 13-52 Standard of Care | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo | Open-Label Period Weeks 33-52 Baxdrostat 2mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 483 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 462 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 21 | 0 | 0 | 0 | 0 |
| Milestone | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Open-Label Period Weeks 13-24 Baxdrostat 2mg | Open-Label Period Weeks 13-52 Standard of Care | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo | Open-Label Period Weeks 33-52 Baxdrostat 2mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 245 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 238 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| Milestone | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Open-Label Period Weeks 13-24 Baxdrostat 2mg | Open-Label Period Weeks 13-52 Standard of Care | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo | Open-Label Period Weeks 33-52 Baxdrostat 2mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 172 | 85 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 163 | 82 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 9 | 3 | 0 |
| Milestone | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Open-Label Period Weeks 13-24 Baxdrostat 2mg | Open-Label Period Weeks 13-52 Standard of Care | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo | Open-Label Period Weeks 33-52 Baxdrostat 2mg |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 245 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 236 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
To assess the effect of 2 mg baxdrostat vs placebo on seated systolic blood pressure (SBP) at 8 weeks after randomised withdrawal (RWD). All available measurements were included, and missing data were multiply imputed.
| mmHg | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo |
|---|---|---|
| Change From Randomised Withdrawal Baseline (Week 24) in Seated Systolic Blood Pressure (SBP) for 2 mg Baxdrostat | -3.7 ± 0.9 | 1.4 ± 1.3 |
To assess the effect of 2 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.
| mmHg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Change From Baseline in Seated SBP for 2 mg Baxdrostat in the Resistant Hypertension Subpopulation | -15.2 ± 1.2 | -5.4 ± 1.3 |
To assess the effect of 2 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.
| mmHg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 2 mg Baxdrostat | -6.9 ± 0.6 | -3.0 ± 0.7 |
To assess the effect of 2 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.
| Participants | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Number of Participants Who Achieved Seated SBP < 130 mmHg for 2 mg Baxdrostat | 106 | 49 |
To assess the effect of 1 mg baxdrostat vs placebo on seated SBP at Week 12 in the resistant hypertension (rHTN) subpopulation. All available measurements were included, and missing data were multiply imputed.
| mmHg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Change From Baseline in Seated SBP for 1 mg Baxdrostat in the Resistant Hypertension Subpopulation | -14.5 ± 1.2 | -5.4 ± 1.3 |
To assess the effect of 1 mg baxdrostat vs placebo on seated diastolic blood pressure (DBP) at Week 12. All available measurements were included, and missing data were multiply imputed.
| mmHg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 1 mg Baxdrostat | -6.3 ± 0.7 | -3.0 ± 0.7 |
To assess the effect of 1 mg baxdrostat vs placebo on achieving seated SBP \< 130 mmHg at Week 12. All available measurements were included, and missing data were multiply imputed.
| Participants | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Number of Participants Who Achieved Seated SBP < 130 mmHg for 1 mg Baxdrostat | 104 | 49 |
To assess the effect of 2 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.
| mmHg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat | -15.7 ± 1.0 | -5.8 ± 1.0 |
To assess the effect of 1 mg baxdrostat versus placebo on seated systolic blood pressure at Week 12. All available measurements were included, and missing data were multiply imputed.
| mmHg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Placebo |
|---|---|---|
| Change From Baseline in Seated Systolic Blood Pressure for 1 mg Baxdrostat | -14.5 ± 1.0 | -5.8 ± 1.0 |
Collected over From first dose of study drug to the end of study at Week 54. Note that the study was analyzed in five analysis periods: Double-Blind Treatment Weeks 0-12 (both cohorts), RWD Weeks 25-32 (C1 only), Weeks 0-24 (both cohorts; including the 2-week safety follow-up (SFU) period till Week 26 for C2), Weeks 0-52 (C1 only; including the 2-week SFU period till Week 54 for C1) and Weeks 13-52 (both cohorts; including the 2-week SFU period till Week 26 for C2 and Week 54 for C1).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | 0/264 (0%) | 5/264 (1.9%) | 49/264 (18.6%) |
| Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | 0/266 (0%) | 9/266 (3.4%) | 64/266 (24.1%) |
| Double-Blind Treatment Period Weeks 0-12 Placebo | 1/264 (0.4%) | 7/264 (2.7%) | 39/264 (14.8%) |
| Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | 0/172 (0%) | 4/172 (2.3%) | 27/172 (15.7%) |
| Randomised Withdrawal Period Weeks 25-32 Placebo | 0/85 (0%) | 0/85 (0%) | 9/85 (10.6%) |
| Weeks 0-24 Analysis Period Baxdrostat | 0/481 (0%) | 33/481 (6.9%) | 145/481 (30.1%) |
| Weeks 0-24 Analysis Period Placebo/Standard of Care | 1/214 (0.5%) | 14/214 (6.5%) | 39/214 (18.2%) |
| Weeks 0-52 Analysis Period Baxdrostat | 1/192 (0.5%) | 23/192 (12%) | 83/192 (43.2%) |
| Weeks 0-52 Analysis Period Placebo/Standard of Care | 1/123 (0.8%) | 9/123 (7.3%) | 25/123 (20.3%) |
| Weeks 13-52 Analysis Period Baxdrostat 2mg | 0/127 (0%) | 6/127 (4.7%) | 44/127 (34.6%) |
| Weeks 13-52 Analysis Period Standard of Care | 0/49 (0%) | 2/49 (4.1%) | 12/49 (24.5%) |
| Event | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo | Weeks 0-24 Analysis Period Baxdrostat | Weeks 0-24 Analysis Period Placebo/Standard of Care | Weeks 0-52 Analysis Period Baxdrostat | Weeks 0-52 Analysis Period Placebo/Standard of Care | Weeks 13-52 Analysis Period Baxdrostat 2mg | Weeks 13-52 Analysis Period Standard of Care |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/264 | 0/266 | 0/264 | 0/172 | 0/85 | 0/481 | 0/214 | 1/192 | 0/123 | 0/127 | 1/49 |
| Cerebral artery embolismNervous system disorders | 0/264 | 0/266 | 0/264 | 0/172 | 0/85 | 0/481 | 0/214 | 0/192 | 0/123 | 0/127 | 1/49 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/264 | 0/266 | 0/264 | 0/172 | 0/85 | 0/481 | 0/214 | 0/192 | 0/123 | 0/127 | 1/49 |
| Cardiac failureCardiac disorders | 0/264 | 0/266 | 0/264 | 0/172 | 0/85 | 0/481 | 2/214 | 0/192 | 2/123 | 0/127 | 0/49 |
| Angina pectorisCardiac disorders | 0/264 | 0/266 | 0/264 | 0/172 | 0/85 | 2/481 | 0/214 | 2/192 | 0/123 | 0/127 | 0/49 |
| Small intestinal obstructionGastrointestinal disorders | 0/264 | 1/266 | 0/264 | 0/172 | 0/85 | 2/481 | 0/214 | 2/192 | 0/123 | 0/127 | 0/49 |
| HaemorrhoidsGastrointestinal disorders | 0/264 | 0/266 | 1/264 | 0/172 | 0/85 | 0/481 | 2/214 | 0/192 | 1/123 | 0/127 | 0/49 |
| Septic shockInfections and infestations | 0/264 | 0/266 | 2/264 | 0/172 | 0/85 | 0/481 | 2/214 | 0/192 | 1/123 | 0/127 | 0/49 |
| HypervolaemiaMetabolism and nutrition disorders | 0/264 | 0/266 | 2/264 | 0/172 | 0/85 | 0/481 | 2/214 | 0/192 | 1/123 | 0/127 | 0/49 |
| Acute myocardial infarctionCardiac disorders | 0/264 | 0/266 | 0/264 | 0/172 | 0/85 | 1/481 | 1/214 | 0/192 | 1/123 | 1/127 | 0/49 |
| Event | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Randomised Withdrawal Period Weeks 25-32 Baxdrostat 2mg | Randomised Withdrawal Period Weeks 25-32 Placebo | Weeks 0-24 Analysis Period Baxdrostat | Weeks 0-24 Analysis Period Placebo/Standard of Care | Weeks 0-52 Analysis Period Baxdrostat | Weeks 0-52 Analysis Period Placebo/Standard of Care | Weeks 13-52 Analysis Period Baxdrostat 2mg | Weeks 13-52 Analysis Period Standard of Care |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 16/264 | 31/266 | 7/264 | 17/172 | 4/85 | 69/466 | 7/208 | 47/73 | 4/47 | 20/62 | 3/29 |
| HyponatraemiaMetabolism and nutrition disorders | 3/264 | 10/266 | 2/264 | 6/172 | 2/85 | 20/466 | 1/208 | 11/73 | 1/47 | 11/62 | 1/29 |
| Upper respiratory tract infectionInfections and infestations | 7/264 | 1/266 | 10/264 | 1/172 | 1/85 | 8/481 | 11/214 | 7/192 | 6/123 | 3/127 | 4/49 |
| HypertensionVascular disorders | 5/264 | 4/266 | 9/264 | 0/172 | 1/85 | 11/481 | 10/214 | 5/192 | 6/123 | 3/127 | 4/49 |
| HypotensionVascular disorders | 6/264 | 10/266 | 2/264 | 0/172 | 0/85 | 18/481 | 2/214 | 13/192 | 4/123 | 7/127 | 0/49 |
| NasopharyngitisInfections and infestations | 8/264 | 8/266 | 6/264 | 3/172 | 1/85 | 23/481 | 7/214 | 11/192 | 5/123 | 5/127 | 1/49 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/264 | 6/266 | 2/264 | 1/172 | 0/85 | 8/481 | 2/214 | 10/192 | 1/123 | 2/127 | 0/49 |
| DizzinessNervous system disorders | 7/264 | 9/266 | 4/264 | 1/172 | 1/85 | 24/481 | 4/214 | 10/192 | 3/123 | 5/127 | 0/49 |
| Age, Continuous(Years) | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Total |
|---|---|---|---|---|
| Mean | 59.8 ± 11.8 | 61.8 ± 11.7 | 61.9 ± 11.6 | 61.1 ± 11.7 |
| Sex: Female, Male(Participants) | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Total |
|---|---|---|---|---|
| Female | 95 | 103 | 102 | 300 |
| Male | 169 | 163 | 162 | 494 |
| Race/Ethnicity, Customized(Participants) | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Total |
|---|---|---|---|---|
| Race : American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race : Asian | 65 | 72 | 72 | 209 |
| Race : Black or African American | 23 | 21 | 15 | 59 |
| Race : Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 2 |
| Race : White | 165 | 168 | 167 | 500 |
| Race : Multiple | 1 | 1 | 0 | 2 |
| Race : Other | 8 | 1 | 7 | 16 |
| Race : Missing | 1 | 3 | 2 | 6 |
| Race/Ethnicity, Customized(Participants) | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Total |
|---|---|---|---|---|
| Ethnicity : Hispanic or Latino | 27 | 39 | 38 | 104 |
| Ethnicity : Not Hispanic or Latino | 231 | 216 | 216 | 663 |
| Ethnicity : Missing | 6 | 11 | 10 | 27 |
| Seated Systolic Blood Pressure(mmHg) | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 1mg | Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg | Double-Blind Treatment Period Weeks 0-12 Placebo | Total |
|---|---|---|---|---|
| Mean | 149.7 ± 10.1 | 149.1 ± 9.1 | 149.0 ± 8.7 | 149.3 ± 9.3 |
Showing the first 100 of 263 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Nov 2023 to primary completion in May 2025, 17 months.
Results were first posted in Jul 2026, 1 year 2 months after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 17 months is close to that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baxdrostat